npj Vaccines

Article	Citations
Author Correction: Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores	299
Assessing immunogenicity barriers of the HIV-1 envelope trimer	232
Reverse development of vaccines against antimicrobial-resistant pathogens	183
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	133
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	113
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	110
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	109
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	100
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	93
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	89
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	79
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	77
Rational development of a combined mRNA vaccine against COVID-19 and influenza	76
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	74
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	71
Mapping global public perspectives on mRNA vaccines and therapeutics	60
The dengue-specific immune response and antibody identification with machine learning	60
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	59
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	58
Protein engineering strategies for rational immunogen design	58
LmCen−/− based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia	57
Immune response against SARS-CoV-2 variants: the role of neutralization assays	57
PfRH5 vaccine; from the bench to the vial	57
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	57
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	56

Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	56
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	54
Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	54
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	50
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	49
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	49
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	48
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	47
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	46
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	45
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	45
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	45
Antibody responses against influenza A decline with successive years of annual influenza vaccination	44
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	43
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	43
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	41
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	40
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	40
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	39
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	39
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	39
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	39
A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9	39
Mobilizing domestic support for international vaccine solidarity – recommendations for health crisis communication	38
A safe insect-based chikungunya fever vaccine affords rapid and durable protection in cynomolgus macaques	37
Dithranol as novel co-adjuvant for non-invasive dermal vaccination	37
Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome	36
Conjugation of HIV-1 envelope to hepatitis B surface antigen alters vaccine responses in rhesus macaques	35
Recombinant lipidated FLIPr effectively enhances mucosal and systemic immune responses for various vaccine types	35
An anti-LpqH human monoclonal antibody from an asymptomatic individual mediates protection against Mycobacterium tuberculosis	34
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression	34
Vaccination of cattle with the Babesia bovis sexual-stage protein HAP2 abrogates parasite transmission by Rhipicephalus microplus ticks	33
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine	32
Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers	32
Assessing the impact of mRNA vaccination in chronic inflammatory murine model	32
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity	32
An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets	32
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection	31
Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity	31
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2	30
Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge	30
Urgency and necessity of Epstein-Barr virus prophylactic vaccines	30
Intranasal COVID-19 vaccine induces respiratory memory T cells and protects K18-hACE mice against SARS-CoV-2 infection	30
Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy	30
Strep A: challenges, opportunities, vaccine-based solutions, and economics	29
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy	29
Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery	29
Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines	29
Long term T cell response and safety of a tetravalent dengue vaccine in healthy children	29
mRNA vaccines induce rapid antibody responses in mice	29

Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization	28
Esoteric beliefs and CAM impact SARS-CoV-2 immunization drivers, uptake and pediatric immunization views in Germany	28
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges	28
Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants	28
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity	28
Novel oral adjuvant to enhance cytotoxic memory like NK cell responses in HIV vaccine platform	27
Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein	27
Continuing development of vaccines and monoclonal antibodies against Zika virus	27
COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children	27
A broadly protective vaccine against cutaneous human papillomaviruses	27
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans	26
A candidate subunit vaccine induces protective immunity against Mycobacterium avium subspecies paratuberculosis in mice	26
Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees	26
Engineering the hydroxyl content on aluminum oxyhydroxide nanorod for elucidating the antigen adsorption behavior	26
The TLR7/8 agonist INI-4001 enhances the immunogenicity of a Powassan virus-like-particle vaccine	25
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant	25
Toxoplasmosis vaccines: what we have and where to go?	24
The Streptococcus pyogenes vaccine landscape	24
C5aR+ dendritic cells fine-tune the Peyer’s patch microenvironment to induce antigen-specific CD8+ T cells	24
Analyzing immune responses to varied mRNA and protein vaccine sequences	23
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge	23
Realising the potential of correlates of protection for vaccine development, licensure and use: short summary	23
Modulation of oral vaccine efficacy by the gut microbiota	23
Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine	22
Deglycosylation of eukaryotic-expressed flagellin restores adjuvanticity	22
Live-attenuated ME49Δcdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis	22
Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection	22
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection	22
Retraction Note: Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies	22
WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58	22
Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19	22
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development	22
Establishing an immune correlate of protection for Nipah virus in nonhuman primates	22
Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection	21
mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response	21
A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice	21
Comparison of rArt v 1-based sublingual and subcutaneous immunotherapy in a murine model of asthma	21
Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns	21
Adenovirus type 5-expressing Gn induces better protective immunity than Gc against SFTSV infection in mice	21
Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase	21
Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens	21
Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis	20
The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness	20
Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population	20
Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG	20
B cells oppose Mycoplasma pneumoniae vaccine enhanced disease and limit bacterial colonization of the lungs	20
Impact of inactivated vaccine on transmission and evolution of H9N2 avian influenza virus in chickens	20
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine	20
Identifying Plasmodium P36 and P52 antigens for coadministration with circumsporozoite protein to enhance vaccine efficacy	20
Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge	20
COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales	20
Streptococcus pyogenes vaccine candidates do not induce autoimmune responses in a rheumatic heart disease model	20
Modified influenza M158–66 peptide vaccination induces non-relevant T-cells and may enhance pathology after challenge	20
Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections	20
NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae	19
A highly immunogenic UVC inactivated Sabin based polio vaccine	19
Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial	19
Oral vaccination stimulates neutrophil functionality and exerts protection in a Mycobacterium avium subsp. paratuberculosis infection model	19
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen	19
HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial	19
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses	19
Genetic ancestry and population structure of vaccinia virus	18
Long-term efficacy of an inactivated H5N1 whole-particle influenza vaccine in nonhuman primates	18
Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance	18
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques	18
Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism	18
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants	18
Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians	18
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial	18
Human naïve B cells show evidence of anergy and clonal redemption following vaccination	17
The scientific journey of a novel adjuvant (AS37) from bench to bedside	17
The full health, economic, and social benefits of prospective Strep A vaccination	17
Vaccine-induced time- and age-dependent mucosal immunity to gastrointestinal parasite infection	17
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2	17
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore	17
A scoping review of global COVID-19 vaccine hesitancy among pregnant persons	17
Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein	17
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice	17
Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination	17
Author Correction: Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests	17

A highly immunogenic vaccine platform against encapsulated pathogens using chimeric probiotic Escherichia coli membrane vesicles	17
Is new dengue vaccine efficacy data a relief or cause for concern?	17
Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus	17
A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system	17
Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort	16
Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	16
Progress with COVID vaccine development and implementation	16
Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles	16
Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination	16
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	16
Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype	16
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging	16
Cyclic di AMP phosphodiesterase nanovaccine elicits protective immunity against Burkholderia cenocepacia infection in mice	16
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines	16
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model	16
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2	16
Precocious Eimeria magna transgenically expressing RHDV P2 subdomain induces immune responses in rabbits	16
The immunological interplay between vaccination and the intestinal microbiota	15
A phase I clinical study to assess safety and immunogenicity of yellow fever vaccine	15
Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children	15
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans	15
Author Correction: The dengue-specific immune response and antibody identification with machine learning	15
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant	15
Divergent B-cell repertoire remodelling by mRNA, DNA and live attenuated vaccines in fish	15
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice	15
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development	15
Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells	15
Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice	15
ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas’ disease	15
CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines	15
A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate	15
Author Correction: Selectively targeting haemagglutinin antigen to chicken CD83 receptor induces faster and stronger immunity against avian influenza	15
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults	15
iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA	14
Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France	14
Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination	14
Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230	14
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy	14
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine	14
Optimization of an alum-anchored clinical HIV vaccine candidate	14
A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates	14
Filovirus vaccines as a response paradigm for emerging infectious diseases	14
An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21	14
Systems vaccinology identifies immunological correlates of SARS-CoV-2 vaccine response in solid organ transplant recipients	14
A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine	14
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza	14
Applying causal inference and Bayesian statistics to understanding vaccine safety signals using a simulation study	14
Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers	13
Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice	13
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2	13
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data	13
A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection	13
Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective	13
Irradiated whole cell Chlamydia vaccine confers significant protection in a murine genital tract challenge model	13
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development	13
Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses	13
The potential global cost-effectiveness of prospective Strep A vaccines and associated implementation efforts	13
Author Correction: An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus	13
Mass cytometry reveals cellular correlates of immune response heterogeneity to SARS-CoV-2 vaccination in the elderly	13
Affordable SARS-CoV-2 protein vaccines for the pandemic endgame	12
A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques	12
Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland	12
A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection	12
Japanese encephalitis virus live attenuated vaccine strains display altered immunogenicity, virulence and genetic diversity	12
Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	12
Author Correction: mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum	12
A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses	12
Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality	12
Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ	12
Serum antibody profiling identifies vaccine-induced correlates of protection against aerosolized ricin toxin in rhesus macaques	12
Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization	12
A systems biology approach to define SARS-CoV-2 correlates of protection	12
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens	12
Identifying vaccine-hesitant subgroups in the Western Pacific using latent class analysis	12
Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease	12
A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2	12
Safety and efficacy of live attenuated PEDV vaccines for neonatal protection	12
Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants	12
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells	12
Differential efficacy of first licensed western vaccines protecting without immunopathogenesis Wuhan-1-challenged hamsters from severe COVID-19	11
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope	11
Interferon as an immunoadjuvant to enhance antibodies following influenza B infection and vaccination in ferrets	11
Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach	11
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys	11
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E	11
An immunological autobiography: my year as a COVID-19 vaccine trial participant	11
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models	11
A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus	11
Immune correlates of protection as a game changer in tuberculosis vaccine development	11
Hepatitis C virus E1 and modified E2 delivered from an mRNA vaccine induces protective immunity	11
Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge	11
Ensuring equity with pre-clinical planning for chlamydia vaccines	11
Author Correction: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine	11
Author Correction: Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination	11
Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C	11